Want to see ATOS full AI Analyst Report?
ATOS Stock Chart & Stats
$2.30
$0.06(2.40%)
At close: 4:00 PM EDT
$2.30
$0.06(2.40%)
Day’s Range― - ―
52-Week Range$1.70 - $19.33
Previous CloseN/A
Volume20.56K
Average Volume (3M)1.16M
Market Cap
$20.65M
Enterprise Value$13.53
Total Cash (Recent Filing)$31.72M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.09
Next Earnings
Aug 17, 2026EPS Estimate
-1.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.37
Shares Outstanding9,974,998
10 Day Avg. Volume1,949,046
30 Day Avg. Volume1,157,820
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)1.94
Price to Sales (P/S)0.00
P/FCF Ratio-2.56
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$16.00Price Target Upside595.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-4.3
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageThe company reports no debt, which reduces long-term interest and repayment pressure and preserves financial flexibility. For a clinical-stage biotech this durable low-leverage profile lowers bankruptcy risk and supports ability to prioritize R&D over mandatory debt service.
Peer-reviewed Preclinical ValidationPublication in npj Breast Cancer reporting multiple novel (Z)-endoxifen–related compounds with activity — including against ESR1 mutation models — provides scientific validation and broadens the therapeutic opportunity set, strengthening long-term development optionality and partner interest.
Governance And Capital-structure FlexibilityStockholder approvals (director elections, auditor ratification, reverse split authorization) maintain board continuity and provide a structural tool to manage listing and capital structure. That governance alignment and flexibility support credible execution over the medium term.
Bears Say
Zero RevenueATOS remains a pre-revenue clinical-stage company, meaning all operations depend on external financing. Persistent $0 revenue over multiple periods eliminates internal cash generation as a buffer and makes long-term viability contingent on successful trials or partner deals.
Widening Losses And Declining EquitySteady depletion of shareholders' equity from cumulative losses weakens the balance sheet and reduces the capital cushion. This structural erosion raises the probability of dilutive financings or restructuring and constrains strategic options if clinical timelines lengthen.
Negative Cash Flow And Accelerating BurnOperating and free cash flow are consistently and increasingly negative, signaling accelerating burn. This durable cash-flow pressure forces near-term external funding, which can dilute shareholders or slow R&D progress if capital access tightens over the next several quarters.
Atossa Therapeutics News
ATOS FAQ
What was Atossa Therapeutics’s price range in the past 12 months?
Atossa Therapeutics lowest stock price was $1.70 and its highest was $19.33 in the past 12 months.
What is Atossa Therapeutics’s market cap?
Atossa Therapeutics’s market cap is $20.65M.
When is Atossa Therapeutics’s upcoming earnings report date?
Atossa Therapeutics’s upcoming earnings report date is Aug 17, 2026 which is in 15 days.
How were Atossa Therapeutics’s earnings last quarter?
Atossa Therapeutics released its earnings results on May 08, 2026. The company reported -$1.11 earnings per share for the quarter, missing the consensus estimate of -$0.99 by -$0.12.
Is Atossa Therapeutics overvalued?
According to Wall Street analysts Atossa Therapeutics’s price is currently Undervalued.
Does Atossa Therapeutics pay dividends?
Atossa Therapeutics does not currently pay dividends.
What is Atossa Therapeutics’s EPS estimate?
Atossa Therapeutics’s EPS estimate is -1.03.
How many shares outstanding does Atossa Therapeutics have?
Atossa Therapeutics has 9,974,998 shares outstanding.
What happened to Atossa Therapeutics’s price movement after its last earnings report?
Atossa Therapeutics reported an EPS of -$1.11 in its last earnings report, missing expectations of -$0.99. Following the earnings report the stock price went down -1.235%.
Which hedge fund is a major shareholder of Atossa Therapeutics?
Currently, no hedge funds are holding shares in ATOS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Atossa Therapeutics
Atossa Therapeutics, Inc. (ATOS) is a clinical-stage biopharmaceutical company focused on developing treatments for breast cancer and related conditions. The company’s activities center on research and development of drug candidates, including (historically) its selective estrogen receptor modulator (SERM) program (such as (Z)-endoxifen) and other therapeutics intended for breast cancer indications. As a clinical-stage company, it does not operate a traditional commercial product portfolio and primarily advances candidates through clinical trials and regulatory development.
ATOS Stock 12 Month Forecast
Average Price Target
$16.00
▲(595.65% Upside)
Technical Analysis
Ownership Overview
2.17% Insiders
27.43% Mutual Funds
<0.01% Other Institutional Investors
66.52% Public Companies and
Individual Investors